Results 81 to 90 of about 6,808 (263)
Quantitative proteomics and systems analysis of cultured H9C2 cardiomyoblasts during differentiation over time supports a ‘function follows form’ model of differentiation [PDF]
, 2018 The rat cardiomyoblast cell line H9C2 has emerged as a valuable tool for studying cardiac development, mechanisms of disease and toxicology. We present here a rigorous proteomic analysis that monitored the changes in protein expression during ...
Clarke, Kylie +8 more
core +2 more sources
Isoform Specificity of a Compound Targeting Actin Filaments Containing Tropomyosin Tpm1.8/1.9
Cytoskeleton, EarlyView.ABSTRACT The unbranched actin filaments in mammalian cells are usually composed of co‐polymers of a specific tropomyosin isoform with actin. Genetic manipulation has revealed that the tropomyosins largely define the functional properties of actin filaments in an isoform‐specific, non‐redundant manner.
Jeff Hook +2 more
wiley +1 more source
Force transmission in epithelial tissues [PDF]
, 2016 In epithelial tissues, cells constantly generate and transmit forces between each other. Forces generated by the actomyosin cytoskeleton regulate tissue shape and structure and also provide signals that influence cells' decisions to divide, die, or ...
Martin, Adam C., Vasquez, Claudia G.
core +1 more source
Fhod3 in zebrafish supports myofibril stability during growth of embryonic skeletal muscle
Developmental Dynamics, EarlyView.Abstract Background Actin filament organization in cardiomyocytes critically depends on the formin Fhod3, but a role for Fhod3 in skeletal muscle development has not yet been described. Results We demonstrate here that in zebrafish mutated for one of two fhod3 paralog genes, fhod3a, skeletal muscle of the trunk appears normal through 2 days post ...
Aubrie Russell +3 more
wiley +1 more source
Functional and biophysical analyses of the class XIV Toxoplasma gondii Myosin D [PDF]
, 2018 Summary: The obligate intracellular parasite Toxoplasma gondii uses gliding motility to migrate across the biological barriers of the host and to invade cells. This unique form of locomotion requires an intact actin cytoskeleton and involves at least one
DELBAC, FRÊDÊRIC +8 more
core
ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
Minimum and Maximum Limit to Number of Myosin II Motors Participating in an Ensemble Motility [PDF]
, 2002 Extensive research on centrifugal compressors has been planned to define diffuser stall limits for a group of stages characterized by low blade-outlet-width-to-impeller-radius-ratio.
Elangovan, Ravikrishnan +4 more
core +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source